Why Did Citius Pharmaceuticals Stock Plunge 29.93%?

On June 10, 2025, Citius experienced a significant drop of 29.93% in pre-market trading, marking a notable decline in its stock performance.

Citius Pharmaceuticals has seen substantial volatility in its stock price recently. On Monday, the company's shares soared by 73.92% to $1.48 during the session, with shareholders witnessing a 21.75% increase in the stock price. This volatility was also evident in the intraday session, where Citius Pharmaceuticals' shares rose by 121.5% to $1.89, reflecting a significant market cap of $19.3 million.

Analysts at H.C. Wainwright revised their price target for Citius Pharmaceuticals, lowering it from $100 to $4 while maintaining a Buy rating. This adjustment comes amidst the company's recent announcements, including a distribution services agreement that has contributed to the stock's upward momentum.

Citius Pharmaceuticals' stock performance has been influenced by its strategic moves and market dynamics. The company's entry into a distribution services agreement has been a key driver, leading to a surge in its stock price. This agreement is part of Citius Pharmaceuticals' broader strategy to develop and commercialize first-in-class critical care products, positioning the company for potential growth in the biopharmaceutical sector.